Citraconate preserves T cell stemness and antitumor immunity
Science Immunology · 2026
DOI: 10.1126/sciimmunol.adz0348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, 2026. Verfasst von Wenhui Li und 25 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medi…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Succinates, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Natural Science Foundation of Jiangsu Province, National key R&D program of China.
Abstract (Originalsprache)
Metabolic perturbations in the tumor microenvironment profoundly compromise the stemlike properties and effector functions of CD8 T cells. Deciphering the metabolic circuitry that sustains T cell stemness is critical for reinvigorating tumor-infiltrating lymphocytes and augmenting immunotherapeutic efficacy. Here, we identify citraconate, an itaconate isomer, as a metabolite markedly depleted in CD8 T cells subjected to chronic antigen stimulation or hypoxic conditions. Citraconate supplementation preserves stemlike characteristics, attenuates ferroptosis, and potentiates T cell–mediated antitumor immunity. Mechanistically, citraconate maintains intracellular cyclic adenosine monophosphate (cAMP) concentrations by suppressing phosphodiesterase1A/C (PDE1A/C) expression and preserving mitochondrial integrity, thereby activating protein kinase A (PKA) signaling. This activation transcriptionally represses arachidonate-5-lipoxygenase (ALOX5), consequently reducing arachidonic acid peroxidation. Clinically, diminished ALOX5 or PDE1A expression correlates with reduced T cell exhaustion and improved responses to immune checkpoint blockade (ICB) therapy. Our findings reveal the citraconate-mediated PDE1-cAMP-ALOX5 axis as a potential therapeutic target for enhancing cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Suzhou 215123, Jiangsu, China.
- Key Laboratory of Synthetic Biology Regulatory Elements, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Suzhou 215123, Jiangsu, China.
- Center for Cancer Diagnosis and Treatment, Second Affiliated Hospital of Soochow University, Suzhou 215123, Jiangsu, China.
- PRAG Therapy Center, Second Affiliated Hospital of Soochow University, Suzhou 215123, Jiangsu, China.
- Department of Oncology, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou 215001, Jiangsu, China.
- Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
ORCID-Profile: Wenhui Li, Minmin Ge, Ziyi Luo, Minju Ni, Kexin Tang, Chenfeng Han, Jiajia Wang, Yifu Ma, Xiaowei Liu, Kaili Ma, Jingxing Yang, Wenjing Li, Cangang Zhang, Qitai Zhao, Guangcan Shao, Jaeoh Park, Yi Zhang, Yonghong Wan, Baojun Zhang, Gang Wang, Mingjing Shen, Qiang Shan, Feng Guo, Ping-Chih Ho, Liyuan Zhang, Lianjun Zhang
Förderung
- National Natural Science Foundation of China
- National Natural Science Foundation of Jiangsu Province
- National key R&D program of China
- CAMS Innovation Fund for Medical Sciences
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- The Suzhou Major Disease Multicenter Clinical Research Project
- Natural Science Foundation Outstanding Youth Fund of Jiangsu Province
Zitieren
APA
Li, W., Ge, M., Luo, Z., Ni, M., Tang, K., Han, C., Wang, J., Ma, Y., Liu, X., Ma, K., Yang, J., Li, W., Zhang, C., Zhao, Q., Shao, G., Park, J., Zhang, Y., Wan, Y., Zhang, B., …, & Zhang, L. (2026). Citraconate preserves T cell stemness and antitumor immunity. Science Immunology. https://doi.org/10.1126/sciimmunol.adz0348
Vancouver
Li W, Ge M, Luo Z, Ni M, Tang K, Han C, et al. Citraconate preserves T cell stemness and antitumor immunity. Science Immunology. 2026. doi:10.1126/sciimmunol.adz0348
BibTeX
@article{Li2026,
author = {Li, Wenhui and Ge, Minmin and Luo, Ziyi and Ni, Minju and Tang, Kexin and Han, Chenfeng and Wang, Jiajia and Ma, Yifu and Liu, Xiaowei and Ma, Kaili and Yang, Jingxing and Li, Wenjing and Zhang, Cangang and Zhao, Qitai and Shao, Guangcan and Park, Jaeoh and Zhang, Yi and Wan, Yonghong and Zhang, Baojun and Wang, Gang and Shen, Mingjing and Shan, Qiang and Guo, Feng and Ho, Ping-Chih and Zhang, Liyuan and Zhang, Lianjun},
title = {Citraconate preserves T cell stemness and antitumor immunity},
journal = {Science Immunology},
year = {2026},
doi = {10.1126/sciimmunol.adz0348}
}
EUVIMED